Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • secondary banner - 3
     
  • Profile: A personalized medicine cancer research study

    William Hahn, MD, PhD, and colleague

    Profile, a research project launched by scientists at Dana-Farber/Brigham and Women's Cancer Center and Dana-Farber/Boston Children's Cancer and Blood Disorders Center, is one of the nation's most comprehensive precision cancer medicine initiatives. Profile is a large-scale cohort research study aimed at collecting as much information and genomic data as possible for every type of cancer. The goal is to use this data to learn more about the genetic and molecular alterations that cause cancer to develop and progress. Researchers will use that information to develop better ways to treat cancer and strategies for preventing it.

    Objectives

    Profile aims to detect genetic alterations in tumors and potentially identify targeted therapies that are most likely to be effective in individual patients. The database of tumor genomic profiling data derived from a very large number of patients linked to clinical information makes Profile a powerful tool for discovery and personalized cancer medicine. This database, which adheres to emerging IT standards, will also support proposals for new research studies and clinical trials.

    Future Developments

    To accommodate this constantly evolving field, the study's platform is designed to scale up to include additional screening for new mutations as they are discovered. Germline genotyping is expected in the future. Whole exome sequencing and then whole genome sequencing will also become part of this program.

    Learn more about Profile

    Learn more about precision cancer medicine